NO20013371D0 - Ekspresjon og eksport av anti-fedme proteiner som Fc- fusjonsproteiner - Google Patents

Ekspresjon og eksport av anti-fedme proteiner som Fc- fusjonsproteiner

Info

Publication number
NO20013371D0
NO20013371D0 NO20013371A NO20013371A NO20013371D0 NO 20013371 D0 NO20013371 D0 NO 20013371D0 NO 20013371 A NO20013371 A NO 20013371A NO 20013371 A NO20013371 A NO 20013371A NO 20013371 D0 NO20013371 D0 NO 20013371D0
Authority
NO
Norway
Prior art keywords
proteins
export
expression
obesity
fusion proteins
Prior art date
Application number
NO20013371A
Other languages
English (en)
Other versions
NO20013371L (no
Inventor
Kin-Ming Lo
Jinyang Zhang
Stephen D Gillies
Original Assignee
Lexigen Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexigen Pharm Corp filed Critical Lexigen Pharm Corp
Publication of NO20013371D0 publication Critical patent/NO20013371D0/no
Publication of NO20013371L publication Critical patent/NO20013371L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20013371A 1999-01-07 2001-07-06 Ekspresjon og eksport av anti-fedmeproteiner som Fc- fusjonsproteiner NO20013371L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11507999P 1999-01-07 1999-01-07
PCT/US2000/000352 WO2000040615A2 (en) 1999-01-07 2000-01-07 EXPRESSION AND EXPORT OF ANTI-OBESITY PROTEINS AS Fc FUSION PROTEINS

Publications (2)

Publication Number Publication Date
NO20013371D0 true NO20013371D0 (no) 2001-07-06
NO20013371L NO20013371L (no) 2001-09-04

Family

ID=22359200

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013371A NO20013371L (no) 1999-01-07 2001-07-06 Ekspresjon og eksport av anti-fedmeproteiner som Fc- fusjonsproteiner

Country Status (16)

Country Link
US (1) US20040053366A1 (no)
EP (1) EP1141013A2 (no)
JP (1) JP2002534962A (no)
KR (1) KR20020007287A (no)
CN (1) CN1341121A (no)
AU (1) AU778939B2 (no)
BR (1) BR0007414A (no)
CA (1) CA2356401A1 (no)
CZ (1) CZ20012406A3 (no)
HU (1) HUP0105090A2 (no)
ID (1) ID30327A (no)
MX (1) MXPA01006922A (no)
NO (1) NO20013371L (no)
SK (1) SK9432001A3 (no)
WO (1) WO2000040615A2 (no)
ZA (1) ZA200105352B (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1037927B1 (en) 1997-12-08 2004-05-19 Lexigen Pharmaceuticals Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
CA2328076C (en) * 1998-04-15 2009-10-06 Lexigen Pharmaceuticals Corporation Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MXPA02001417A (es) * 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
ES2269366T3 (es) 2000-02-11 2007-04-01 Merck Patent Gmbh Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos.
DE60129695T2 (de) * 2000-06-29 2008-06-05 Merck Patent Gmbh Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
US7189830B2 (en) * 2001-02-19 2007-03-13 Merck Patent Gmbh Anti-KSA/IL-2 fusion proteins with reduced immunogenicity
KR100899970B1 (ko) 2001-02-19 2009-05-28 메르크 파텐트 게엠베하 Ｔ-세포 에피토프의 동정 방법 및 감소된 면역원성을 갖는분자의 제조를 위한 용도
CN1330664C (zh) * 2001-03-07 2007-08-08 默克专利有限公司 用于含杂合同种型抗体部分的蛋白质的表达技术
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
CN100503639C (zh) * 2001-05-03 2009-06-24 默克专利有限公司 重组肿瘤特异性抗体及其应用
MXPA04005266A (es) * 2001-12-04 2004-10-11 Merck Patent Gmbh Inmunocitocinas con selectividad modulada.
US7169904B2 (en) * 2002-12-17 2007-01-30 Emd Lexigen Research Center Corp. Immunocytokine sequences and uses thereof
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
EP1697415A1 (en) 2003-11-12 2006-09-06 Biogen Idec MA Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
CN103212084B (zh) 2003-11-13 2018-07-13 韩美科学株式会社 含有免疫球蛋白fc区作为载体的药物组合物
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
WO2005063820A2 (en) * 2003-12-30 2005-07-14 Merck Patent Gmbh Il-7 fusion proteins
DK1699821T3 (da) * 2003-12-31 2012-07-16 Merck Patent Gmbh Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MED FORBEDREDE FARMAKOKINETIKKER
CA2552590A1 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
WO2005070967A2 (en) * 2004-01-22 2005-08-04 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US7589179B2 (en) * 2004-12-09 2009-09-15 Merck Patent Gmbh IL-7 variants with reduced immunogenicity
ES2408704T3 (es) 2005-01-05 2013-06-21 Biogen Idec Ma Inc. Moléculas de unión a Cripto
US7566456B2 (en) * 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
KR20080050576A (ko) * 2005-07-29 2008-06-09 앰프로틴 코포레이션 키메릭 치료제
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
EP1801121A1 (en) * 2005-12-23 2007-06-27 CONARIS research institute AG Soluble gp130 molecule variants useful as a medicament
PT2270050E (pt) 2005-12-30 2013-09-12 Merck Patent Gmbh Anticorpos anti-cd19 com imunogenicidade reduzida
ES2384055T3 (es) 2005-12-30 2012-06-28 Merck Patent Gmbh Variantes de la interleucina-12p40 con estabilidad mejorada
US7846434B2 (en) * 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
US20080227669A1 (en) * 2007-03-12 2008-09-18 Halliburton Energy Services, Inc. Corrosion-inhibiting additives, treatment fluids, and associated methods
CA2725143A1 (en) 2008-05-21 2009-11-26 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
KR20120024529A (ko) 2008-11-04 2012-03-14 니콜라오스 테자프시디스 신경섬유 매듭 및 아밀로이드 베타의 축적으로부터 기인하는 진행성 인지 기능 장애의 치료용 렙틴 조성물 및 치료 방법
CA2759333A1 (en) 2009-04-22 2010-10-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
CA2832581C (en) 2011-04-08 2022-08-23 Yumei Xiong Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP3626739A1 (en) 2011-06-24 2020-03-25 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
BR112014018575A2 (pt) 2012-01-26 2017-07-04 Amgen Inc polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
PL2880170T3 (pl) 2012-08-02 2017-02-28 F.Hoffmann-La Roche Ag SPOSÓB WYTWARZANIA ROZPUSZCZALNEGO FcR JAKO FUZJI Fc Z OBOJĘTNYM REGIONEM Fc IMMUNOGLOBULINY I JEGO ZASTOSOWANIA
EP2880169B1 (en) 2012-08-02 2017-05-17 F. Hoffmann-La Roche AG Method for producing monomeric and multimeric molecules and uses thereof
SG11201500682WA (en) * 2012-09-07 2015-02-27 Sanofi Sa Fusion proteins for treating a metabolic syndrome
AU2014296107B2 (en) * 2013-07-31 2018-07-26 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CA3014498A1 (en) 2016-03-21 2017-09-28 Children's Medical Center Corporation Compositions and methods for inhibiting wnt signaling
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US20180009869A1 (en) * 2016-07-08 2018-01-11 AskGene Pharma, Inc. Fusion Protein Comprising Leptin and Methods for Producing and Using the Same
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
PE20201350A1 (es) 2018-04-09 2020-11-30 Amgen Inc Proteinas de fusion del factor de diferenciacion de crecimiento 15
US11197910B1 (en) * 2020-08-19 2021-12-14 Vitruviae LLC Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
WO1996031526A1 (en) * 1995-04-06 1996-10-10 Amylin Pharmaceuticals, Inc. Anti-obesity agents
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound

Also Published As

Publication number Publication date
CN1341121A (zh) 2002-03-20
AU2602500A (en) 2000-07-24
SK9432001A3 (en) 2003-02-04
HUP0105090A2 (hu) 2002-04-29
JP2002534962A (ja) 2002-10-22
WO2000040615A3 (en) 2000-11-23
US20040053366A1 (en) 2004-03-18
NO20013371L (no) 2001-09-04
ZA200105352B (en) 2002-06-28
BR0007414A (pt) 2001-10-16
EP1141013A2 (en) 2001-10-10
CZ20012406A3 (cs) 2002-03-13
CA2356401A1 (en) 2000-07-13
MXPA01006922A (es) 2002-04-24
ID30327A (id) 2001-11-22
KR20020007287A (ko) 2002-01-26
AU778939B2 (en) 2004-12-23
WO2000040615A2 (en) 2000-07-13

Similar Documents

Publication Publication Date Title
NO20013371D0 (no) Ekspresjon og eksport av anti-fedme proteiner som Fc- fusjonsproteiner
HUP0201474A3 (en) Expression and export of interferon-alpha proteins as fc fusion proteins
NO20002835D0 (no) 2-aryl-oksodihydropurinderivater, fremgangsmÕte for fremstilling av disse medisinske preparater inneholdende disse, og mellomprodukter derfor
NO995134L (no) Forbedrede fremgangsmåter for fremstilling av aktivert protein C
NO20051645L (no) Nye aminoindozolderivater som medisin og farmakologiske preparater inneholdende disse
IS4345A (is) Setin N-(indól-2-karbónýl)-b-alaninamíð, notkun þeirra og lyfjaefnablöndur
AU6058500A (en) Fusion protein and uses thereof
DK1233964T3 (da) Ny anvendelse og hidtil ukendte N-azabicycloamidderivater
NO993868D0 (no) 3-piperidyl-4-oksokinazolin-derivater og medisinske preparater som inneholder slike
NO991350L (no) Br°nnboringer som benytter fiberoptisk baserte sensorer og operasjonsanordninger
NO20000294D0 (no) Derivater av acylpiperazinylpyrimidiner, deres fremstilling og anvendelse som legemidler
NO20044916L (no) Preparater av sulfinylacetamid
DE69900363T2 (de) Quarzglasgegenstand und dessen Herstellung
NO307510B1 (no) Bicykliske aromatiske forbindelser, deres anvendelse og farmasøytiske og kosmetiske preparater derav
DE10084967T1 (de) Kombinierte Entzerrungs- und Dekodierungstechnik
NO20040249L (no) Blodgruppeantigenfusjonspolypeptider og fremgangsmater for deres anvendelse
NO20016247D0 (no) Streptograminderivater, deres fremstilling og preparater inneholdende derivatene
NO20021275D0 (no) Transgent produserte fusjonsproteiner
AU2002251999A1 (en) Methods and compositions for the construction and use of fusion libraries using computational protein design methods
AU3923000A (en) Agp-1 fusion protein compositions and methods
DE69823225D1 (de) Fusionsproteine, bestehend aus proteinaseinhibitoren
FI953422A0 (fi) Autolysoivia fuusioproteiineja hyväksikäyttävät ilmentämisjärjestelmät ja uusi pelkistävä polypeptidi
DK1165528T3 (da) Hidtil ukendte morpholinoderivater, fremgangsmåde til fremstilling af disse og farmaceutiske præparater indeholdende disse
AU2002322416A1 (en) Gfp fusion proteins and their use
FI971085A0 (fi) Uusia PKA:ta sitovia proteiineja ja näiden käyttömuotoja

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application